liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomised trial of a novel hydrocortisone dual-release formulation
Sahlgrenska Academy, University of Gothenburg.
Sahlgrenska Academy, University of Gothenburg.
Sahlgrenska Academy, University of Gothenburg.
Skånes University Hospital, Malmö.
Visa övriga samt affilieringar
2012 (Engelska)Ingår i: Journal of Clinical Endocrinology and Metabolism, ISSN 0021-972X, E-ISSN 1945-7197, Vol. 97, nr 2, s. 473-481Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Context: Patients with treated adrenal insufficiency (AI) have increased morbidity and mortality rate. Our goal was to improve outcome by developing a once-daily (OD) oral hydrocortisone dual-release tablet with a more physiological exposure-time cortisol profile.

Objective: The aim was to compare pharmacokinetics and metabolic outcome between OD and the same daily dose of thrice-daily (TID) dose of conventional hydrocortisone tablets.

Design and Setting: We conducted an open, randomized, two-period, 12-wk crossover multicenter trial with a 24-wk extension at five university hospital centers.

Patients: The trial enrolled 64 adults with primary AI; 11 had concomitant diabetes mellitus (DM).

Intervention: The same daily dose of hydrocortisone was administered as OD dual-release or TID.

Main Outcome Measure: We evaluated cortisol pharmacokinetics.

Results: Compared with conventional TID, OD provided a sustained serum cortisol profile 0-4 h after the morning intake and reduced the late afternoon and the 24-h cortisol exposure. The mean weight (difference = -0.7 kg, P = 0.005), systolic blood pressure (difference = -5.5 mm Hg, P = 0.0001) and diastolic blood pressure (difference: -2.3 mm Hg; P = 0.03), and glycated hemoglobin (absolute difference = -0.1%, P = 0.0006) were all reduced after OD compared with TID at 12 wk. Compared with TID, a reduction in glycated hemoglobin by 0.6% was observed in patients with concomitant DM during OD (P = 0.004).

Conclusion: The OD dual-release tablet provided a more circadian-based serum cortisol profile. Reduced body weight, reduced blood pressure, and improved glucose metabolism were observed during OD treatment. In particular, glucose metabolism improved in patients with concomitant DM.

Ort, förlag, år, upplaga, sidor
The Endocrine Society , 2012. Vol. 97, nr 2, s. 473-481
Nationell ämneskategori
Medicin och hälsovetenskap
Identifikatorer
URN: urn:nbn:se:liu:diva-76270DOI: 10.1210/jc.2011-1926ISI: 000301226800043OAI: oai:DiVA.org:liu-76270DiVA, id: diva2:513248
Anmärkning

funding agencies|DuoCort Pharma AB||Swedish Foundation of Strategic Research||        

Tillgänglig från: 2012-04-01 Skapad: 2012-04-01 Senast uppdaterad: 2017-12-07

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltext

Personposter BETA

Ekman, BertilWahlberg, Jeanette

Sök vidare i DiVA

Av författaren/redaktören
Ekman, BertilWahlberg, Jeanette
Av organisationen
EndokrinologiHälsouniversitetetEndokrinmedicinska enheten
I samma tidskrift
Journal of Clinical Endocrinology and Metabolism
Medicin och hälsovetenskap

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetricpoäng

doi
urn-nbn
Totalt: 230 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf